O n Wednesday, Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook.

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Pharmaceutical giant Moderna, Inc. (NASDAQ:MRNA) saw its share prices drop by 9.39 percent on Wednesday to close at $40.72 each after investment banking firm Goldman Sachs downgraded Moderna’s ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BRSE:0QF) from Buy to Neutral. There are 1,448 funds or institutions reporting positions in Moderna.

Goldman Sachs would consider acquisitions in asset and wealth management, but would be highly selective about any deal, CEO ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...